Citius Pharmaceuticals Stock Analysis
CTXR Stock | USD 3.22 0.10 3.01% |
Citius Pharmaceuticals is undervalued with Real Value of 3.72 and Target Price of 5.33. The main objective of Citius Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Citius Pharmaceuticals is worth, separate from its market price. There are two main types of Citius Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Citius Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Citius Pharmaceuticals is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Citius Stock trading window is adjusted to America/New York timezone.
Citius |
Citius Stock Analysis Notes
About 17.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.29. Some equities with similar Price to Book (P/B) outperform the market in the long run. Citius Pharmaceuticals recorded a loss per share of 0.24. The entity last dividend was issued on the 9th of June 2017. The firm had 1:15 split on the 9th of June 2017. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Citius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. For more info on Citius Pharmaceuticals please contact Myron Holubiak at 908 967 6677 or go to https://citiuspharma.com.Citius Pharmaceuticals Investment Alerts
Citius Pharmaceuticals generated a negative expected return over the last 90 days | |
Citius Pharmaceuticals has high historical volatility and very poor performance | |
Net Loss for the year was (32.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Citius Pharmaceuticals currently holds about 48.04 M in cash with (29.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
Citius Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
Latest headline from thelincolnianonline.com: Citius Pharmaceuticals Shares Gap Down Whats Next |
Citius Pharmaceuticals Upcoming and Recent Events
9th of February 2024 Upcoming Quarterly Report | View | |
10th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
3rd of January 2025 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
30th of September 2023 Last Financial Announcement | View |
Citius Largest EPS Surprises
Earnings surprises can significantly impact Citius Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-12 | 2024-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2024-05-14 | 2024-03-31 | -0.06 | -0.05 | 0.01 | 16 | ||
2023-08-14 | 2023-06-30 | -0.05 | -0.06 | -0.01 | 20 |
Citius Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Citius Pharmaceuticals' ESG score is a quantitative measure that evaluates Citius Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Citius Pharmaceuticals' operations that may have significant financial implications and affect Citius Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Citius Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Wealth Advisory Solutions, Llc | 2024-09-30 | 201 K | Arkadios Wealth Advisors | 2024-09-30 | 200 K | Susquehanna International Group, Llp | 2024-09-30 | 165.1 K | Bank Of America Corp | 2024-06-30 | 159.4 K | Inspire Advisors, Llc | 2024-09-30 | 157.9 K | Point72 Asia (singapore) Pte. Ltd | 2024-09-30 | 100.5 K | Miller Investment Management, Lp | 2024-09-30 | 99.6 K | Xtx Topco Ltd | 2024-09-30 | 93.3 K | Kestra Advisory Services, Llc | 2024-09-30 | 92.5 K | Armistice Capital, Llc | 2024-09-30 | 7.3 M | Vanguard Group Inc | 2024-09-30 | 6.4 M |
Citius Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.15 M.Citius Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.84) | (0.88) | |
Return On Capital Employed | (0.43) | (0.41) | |
Return On Assets | (0.28) | (0.30) | |
Return On Equity | (0.41) | (0.39) |
Management Efficiency
Citius Pharmaceuticals has return on total asset (ROA) of (0.2474) % which means that it has lost $0.2474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4149) %, meaning that it created substantial loss on money invested by shareholders. Citius Pharmaceuticals' management efficiency ratios could be used to measure how well Citius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/03/2024, Return On Tangible Assets is likely to drop to -0.88. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Citius Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 12/03/2024, Total Current Assets is likely to grow to about 41.5 M, while Non Currrent Assets Other are likely to drop slightly above 41.6 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.56 | 1.04 | |
Tangible Asset Value | -41.3 K | -43.3 K | |
Tangible Book Value Per Share | 0.14 | 0.15 | |
Enterprise Value Over EBITDA | (60.63) | (63.66) | |
Price Book Value Ratio | 24.77 | 26.01 | |
Enterprise Value Multiple | (60.63) | (63.66) | |
Price Fair Value | 24.77 | 26.01 | |
Enterprise Value | 3.9 B | 4.1 B |
The management strategies employed by Citius Pharmaceuticals' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.663 | Return On Assets (0.25) | Return On Equity (0.41) |
Technical Drivers
As of the 3rd of December, Citius Pharmaceuticals shows the Risk Adjusted Performance of (0.16), mean deviation of 5.39, and Standard Deviation of 8.48. Citius Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Citius Pharmaceuticals market risk adjusted performance and treynor ratio to decide if Citius Pharmaceuticals is priced correctly, providing market reflects its regular price of 3.22 per share. Given that Citius Pharmaceuticals has information ratio of (0.23), we suggest you to validate Citius Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Citius Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-seven with a total number of output elements of thirty-four. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Citius Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Citius Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Citius Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Citius Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Citius Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Citius Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Citius Pharmaceuticals Outstanding Bonds
Citius Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Citius Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Citius bonds can be classified according to their maturity, which is the date when Citius Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
C 5240588 25 JAN 26 Corp BondUS17327CAP86 | View | |
C 3057 25 JAN 33 Corp BondUS17327CAQ69 | View | |
C 2014 25 JAN 26 Corp BondUS17327CAN39 | View | |
CITIGROUP INC Corp BondUS17327CAM55 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
US17328WP446 Corp BondUS17328WP446 | View |
Citius Pharmaceuticals Predictive Daily Indicators
Citius Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Citius Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Citius Pharmaceuticals Corporate Filings
F3 | 27th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 25th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
18th of November 2024 Other Reports | ViewVerify | |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 13th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Citius Pharmaceuticals Forecast Models
Citius Pharmaceuticals' time-series forecasting models are one of many Citius Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Citius Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Citius Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Citius Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Citius shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Citius Pharmaceuticals. By using and applying Citius Stock analysis, traders can create a robust methodology for identifying Citius entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Citius Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Citius analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Citius analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
5.33 | Buy | 3 | Odds |
Most Citius analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Citius stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Citius Pharmaceuticals, talking to its executives and customers, or listening to Citius conference calls.
Citius Stock Analysis Indicators
Citius Pharmaceuticals stock analysis indicators help investors evaluate how Citius Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Citius Pharmaceuticals shares will generate the highest return on investment. By understating and applying Citius Pharmaceuticals stock analysis, traders can identify Citius Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 41.7 M | |
Common Stock Shares Outstanding | 151.3 M | |
Total Stockholder Equity | 90.8 M | |
Tax Provision | 576 K | |
Property Plant And Equipment Net | 455.9 K | |
Cash And Short Term Investments | 26.5 M | |
Cash | 26.5 M | |
Accounts Payable | 2.9 M | |
Net Debt | -26 M | |
50 Day M A | 0.4458 | |
Total Current Liabilities | 5.8 M | |
Other Operating Expenses | 36.7 M | |
Non Current Assets Total | 69.2 M | |
Forward Price Earnings | 9.1324 | |
Non Currrent Assets Other | 38.1 K | |
Stock Based Compensation | 6.6 M |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.